2024
Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting.
Santucci M, Ansari M, Nikayin S, Radhakrishnan R, Rhee T, Wilkinson S. Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting. The Journal Of Clinical Psychiatry 2024, 85 PMID: 39361411, DOI: 10.4088/jcp.24m15376.Peer-Reviewed Original ResearchConceptsBipolar depressionAcute seriesRisk of affective switchDiagnosis of bipolar depressionRefractory bipolar depressionAcute phaseMADRS scoreAffective switchIntranasal esketamineManic episodesBipolar disorderCohort of patientsAttending psychiatristsSource of morbidityEsketamineSample of patientsIV ketamineMaintenance treatmentDepressionClinical responseHeightened riskClinical outcomesMania/hypomaniaKetamineKetamine/esketamine
2023
A leaky umbrella has little value: evidence clearly indicates the serotonin system is implicated in depression
Jauhar S, Arnone D, Baldwin D, Bloomfield M, Browning M, Cleare A, Corlett P, Deakin J, Erritzoe D, Fu C, Fusar-Poli P, Goodwin G, Hayes J, Howard R, Howes O, Juruena M, Lam R, Lawrie S, McAllister-Williams H, Marwaha S, Matuskey D, McCutcheon R, Nutt D, Pariante C, Pillinger T, Radhakrishnan R, Rucker J, Selvaraj S, Stokes P, Upthegrove R, Yalin N, Yatham L, Young A, Zahn R, Cowen P. A leaky umbrella has little value: evidence clearly indicates the serotonin system is implicated in depression. Molecular Psychiatry 2023, 28: 3149-3152. PMID: 37322065, PMCID: PMC10618084, DOI: 10.1038/s41380-023-02095-y.Peer-Reviewed Original ResearchRole of Psychedelics in Treatment-Resistant Depression
Kamal S, Jha M, Radhakrishnan R. Role of Psychedelics in Treatment-Resistant Depression. Psychiatric Clinics Of North America 2023, 46: 291-305. PMID: 37149346, DOI: 10.1016/j.psc.2023.02.004.Peer-Reviewed Original Research